Amgen — Feb 3, 2026 release

$Billions, except shares Q4 ’25 Q4 ’24 YOY Δ FY '25 FY '24 YOY Δ Operating Cash Flow $ 1.6  $ 4.8  $ (3.2) $ 10.0  $ 11.5  $ (1.5) Capital Expenditures $ 0.6  $ 0.4  $ 0.3  $ 1.9  $ 1.1  $ 0.8  Free Cash Flow $ 1.0  $ 4.4  $ (3.4) $ 8.1  $ 10.4  $ (2.3) Dividends Paid $ 1.3  $ 1.2  $ 0.1  $ 5.1  $ 4.8  $ 0.3  Share Repurchases $ 0.0  $ 0.2  $ (0.2) $ 0.0  $ 0.2  $ (0.2) Average Diluted Shares (millions) 543  542  1  542  541  1  Note: Numbers may not add due to rounding $Billions 12/31/25 12/31/24 YTD Δ Cash and Cash Equivalents $ 9.1  $ 12.0  $ (2.8) Debt Outstanding $ 54.6  $ 60.1  $ (5.5) Note: Numbers may not add due to rounding 2026 Guidance For the full year 2026, the Company expects: • Total revenues in the range of $37.0 billion to $38.4 billion. • On a GAAP basis, EPS in the range of $15.45 to $16.94, and a tax rate in the range of 15.5% to 17.0%. • On a non-GAAP basis, EPS in the range of $21.60 to $23.00, and a tax rate in the range of 16.0% to 17.5%. • Capital expenditures to be approximately $2.6 billion. • Share repurchases not to exceed $3 billion. Fourth Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). • MARITIME-1, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, without Type 2 diabetes (T2D). • MARITIME-2, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, with T2D. AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Page 11 • MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes, is enrolling adults living with established